Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137831 | 1.00 | MAPT (0.42) | MAPTEPHX1ZDHHC7ACHESMPD1 | |
| SCHEMBL2133664 | 0.99 | MAPT (0.40) | MAPTEPHX1ZDHHC7ACHESMPD1 | |
| SCHEMBL2134886 | 0.97 | MAPT (0.39) | MAPTEPHX1ZDHHC7ACHESMPD1 | |
| SCHEMBL2136160 | 0.97 | MAPT (0.39) | MAPTEPHX1ZDHHC7ACHESMPD1 | |
| SCHEMBL2137059 | 0.96 | MAPT (0.37) | MAPTEPHX1ZDHHC7ACHE | |
| SCHEMBL2136193 | 0.94 | MAPT (0.42) | MAPTEPHX1ZDHHC7ACHESMPD1 | |
| SCHEMBL2136460 | 0.94 | MAPT (0.42) | MAPTEPHX1ZDHHC7ACHESMPD1 | |
| SCHEMBL2134263 | 0.93 | MAPT (0.37) | MAPTEPHX1ZDHHC7ACHE | |
| SCHEMBL2133408 | 0.93 | MAPT (0.37) | MAPTEPHX1ZDHHC7ACHE | |
| SCHEMBL2137576 | 0.93 | MAPT (0.40) | MAPTEPHX1ZDHHC7ACHENAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2664613-A1 | Process for producing amide compounds | Sumitomo Chemical Company, Limited (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-2662355-A1 | Process for producing a (fluoroalkylthio) acetonitrile | Sumitomo Chemical Company, Limited (JP) | 2013-11-13 | — | — | EP | disclosed |
| EP-2465846-A1 | PROCESS FOR PREPARATION OF (FLUOROALKYLTHIO)ACETIC ACID ESTERS | Sumitomo Chemical Company, Limited (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20120101294-A1 | PROCESS FOR PRODUCING (FLUOROALKYLTHIO) ACETIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101294-A1 | PROCESS FOR PRODUCING (FLUOROALKYLTHIO) ACETIC ACID ESTER | GRHPR, AKR7A2, FAR1 | MAPT 4195/4885EPHX1 2018/4885ZDHHC7 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.